Search results
Showing 676 to 690 of 1397 results for 0
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
attentional, emotional and behavioural problems in children born before 28+0 weeks' gestation What is the accuracy of the...
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.
View recommendations for HTG249Show all sections
Sections for HTG249
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (HTG451)
Evidence-based recommendations on total distal radioulnar joint replacement for symptomatic joint instability or arthritis in adults. This involves removing the wrist end of the ulna and replacing it with a metal prosthesis that also attaches to the wrist end of the radius.
Evidence-based recommendations on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease. This involves applying low-energy electrical impulses to the sphincter to strengthen the muscle so that less reflux happens.
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)
Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.
View recommendations for HTG124Show all sections
Sections for HTG124
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.